227 related articles for article (PubMed ID: 17605001)
1. Physiological and pathological properties of alpha-synuclein.
Tofaris GK; Spillantini MG
Cell Mol Life Sci; 2007 Sep; 64(17):2194-201. PubMed ID: 17605001
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein dysfunction in Lewy body diseases.
Tofaris GK; Spillantini MG
Mov Disord; 2005 Aug; 20 Suppl 12():S37-44. PubMed ID: 16092089
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease and α-synuclein expression.
Devine MJ; Gwinn K; Singleton A; Hardy J
Mov Disord; 2011 Oct; 26(12):2160-8. PubMed ID: 21887711
[TBL] [Abstract][Full Text] [Related]
5. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
Roberts RF; Wade-Martins R; Alegre-Abarrategui J
Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
[TBL] [Abstract][Full Text] [Related]
6. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.
Uversky VN; Eliezer D
Curr Protein Pept Sci; 2009 Oct; 10(5):483-99. PubMed ID: 19538146
[TBL] [Abstract][Full Text] [Related]
7. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
8. The good and bad of therapeutic strategies that directly target α-synuclein.
Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
[TBL] [Abstract][Full Text] [Related]
9. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.
Kawahata I; Finkelstein DI; Fukunaga K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892
[TBL] [Abstract][Full Text] [Related]
11. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation.
Kim YM; Jang WH; Quezado MM; Oh Y; Chung KC; Junn E; Mouradian MM
J Neurol Sci; 2011 Aug; 307(1-2):157-61. PubMed ID: 21641618
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of alpha-synuclein neurodegeneration.
Waxman EA; Giasson BI
Biochim Biophys Acta; 2009 Jul; 1792(7):616-24. PubMed ID: 18955133
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease.
Wassouf Z; Schulze-Hentrich JM
J Neurochem; 2019 Sep; 150(5):591-604. PubMed ID: 31165472
[TBL] [Abstract][Full Text] [Related]
16. Exploring the accessible conformations of N-terminal acetylated α-synuclein.
Moriarty GM; Janowska MK; Kang L; Baum J
FEBS Lett; 2013 Apr; 587(8):1128-38. PubMed ID: 23499431
[TBL] [Abstract][Full Text] [Related]
17. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
Junn E; Ronchetti RD; Quezado MM; Kim SY; Mouradian MM
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2047-52. PubMed ID: 12576551
[TBL] [Abstract][Full Text] [Related]
18. Pathological roles of α-synuclein in neurological disorders.
Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between alpha-synuclein and Parkinson's disease].
Nishioka K; Hattori N
Brain Nerve; 2007 Aug; 59(8):825-30. PubMed ID: 17713118
[TBL] [Abstract][Full Text] [Related]
20. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
Lee YC; Hsu SD
Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
